An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Vafidemstat (Primary)
- Indications Aggression
- Focus Adverse reactions
- Acronyms REIMAGINE
- Sponsors Oryzon
- 22 Oct 2018 According to an Oryzon media release, a written communication using transcription phenotypes to utilise in this trial methodology will be presented at the Clinical Trials: Methodology session in the 11th Clinical Trials on Alzheimer's Disease international conference, CTAD-2018.
- 09 Oct 2018 According to an Oryzon media release, first patient has been enrolled in this trial. Dr. Jose Antonio Ramos-Quiroga (head of the Psychiatry Service of the Valle-Hebron hospital) is the principal investigator of this trial.
- 17 Sep 2018 New trial record